Back

Rakovina and Celvion to use AI platform for ATR inhibitor program

Verifying
  • Rakovina and Celvion launched a research collaboration focused on Rakovina’s ATR inhibitor program.
  • EMphora will analyze clinical outcomes and real-world patient data for targets, combinations and biomarkers.
  • Rakovina and Celvion intend to commit resources and explore co-development arrangements as opportunities emerge.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.